ESR1 and neoplasm: These results suggest that the development of novel molecular therapies targeting the Aurora-A/SMAD5 oncogenic axis may be beneficial for the selective eradication of endocrine resistant ERalpha- cancer cells from the bulk tumor with benefits for breast cancer patients [243].